BioSpace News Archive

RaySearch Laboratories AB announces that Torbjörn Wingårdh has been appointed new CFO of the company, taking up his position November 15.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration), announced that the results of the initial randomized, double-masked, placebo-controlled, phase 3 clinical trial of RGN-259 for the treatment of neurotrophic keratitis will be presented at the 2021 American Ophthalmology Association meeting in New Orleans, LA on November 12-15.

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that it will report third quarter financial results on Monday, November 8, 2021, after the market close.

ANI Pharmaceuticals, Inc. announced that the Company will release its third quarter 2021 financial results on Monday, November 1, 2021.

Merck, known as MSD outside the United States and Canada, announced that it has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Merck’s pending acquisition of Acceleron Pharma Inc.

Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization.

Elekta announced the presentation of new award-winning abstracts supporting the many benefits of Elekta Unity in treating cancer patients using precision radiation therapy.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement with Gavi, the Vaccine Alliance to supply up 116.5 million doses of Moderna’s COVID-19 vaccine to be delivered in the second quarter of 2022.

Vaso Corporation announces the amendment of the sales representation agreement between its subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, and GE Healthcare, the healthcare business unit of General Electric Company, originally signed on May 19, 2010.

Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system therapies, announced publication of results from its Phase 3 pivotal efficacy study in the November 2021 Journal of Child and Adolescent Psychopharmacology.